The latest findings from the 2023 Diabetes Care Survey highlight the promising landscape of remote patient monitoring (RPM) for individuals grappling with Type 2 diabetes in the United States. The survey underscores the effectiveness of Cellular RPM™ programs, with an impressive 71% of participants acknowledging their value in tracking health progress between traditional office visits. This marks a substantial increase from the 2021 survey, where only 35% recognised the potential of RPM programs for diabetes management. The surge in awareness suggests a growing satisfaction with the ease and efficacy of cellular remote glucose monitoring programs.
With approximately 33 million Americans contending with Type 2 diabetes, a concerning 45% struggle to maintain adequate control over their glucose levels. The importance of regular at-home glucose testing cannot be overstated, and this is where cellular-enabled glucose monitors step in as user-friendly tools. Their convenience not only facilitates better patient adherence to care plan instructions but also contributes to stabilised or improved health outcomes.
Digging into the survey details, a noteworthy 62% of participants express a willingness to engage in more consistent testing if their results are automatically transmitted to their healthcare providers. This insight becomes particularly crucial considering the infrequent visits individuals with Type 2 diabetes make to their doctors, typically two times a year or less. The manual recording of readings over extended periods raises concerns about the accuracy of written glucose logs, a point emphasised by Dr. Ronald Tamler from the Mount Sinai Diabetes Center.
Addressing these concerns, Smart Meter's cellular-enabled remote glucose monitoring solutions offer a promising avenue for patients and healthcare providers alike. These solutions provide real-time, secure, and accurate data transmission, addressing the need for reliable tools in diabetes management.
Click here to read the original news story.